Last reviewed · How we verify

NCT03809754

Optical Coherence Tomography Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis

Status unknown NA Last updated 23 January 2019
What this trial tests

NA trial testing Percutaneous Coronary Intervention under OCT in CHD - Coronary Heart Disease in 240 participants. Status unknown.

Timeline
1 March 2019
Primary endpoint
1 March 2020
1 September 2020

Quick facts

Lead sponsorChinese PLA General Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment240
Start date1 March 2019
Primary completion1 March 2020
Estimated completion1 September 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

18 and older, any sex, with CHD - Coronary Heart Disease or Percutaneous Coronary Intervention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, registry trial aimed to compare the clinical and angiographic outcomes of OCT-guided and angiography-guided PCI in patients with coronary DES-ISR.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Clinical Significance of Optical Coherence Tomography-Guided Percutaneous Coronary Intervention for In-Stent Restenosis Within Drug-Eluting Stents: Impact on Patient Outcomes.
    Han Y, Yuan X, Wang W, Wang N, et al · · 2024 · cited 1× · PMID 39494577 · DOI 10.1161/jaha.123.033954

Verify or expand the search:

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03809754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing